Fox Jonathan C 4

What Happened
Jonathan C. Fox, a director of Edgewise Therapeutics, received a grant of 16,377 derivative securities (stock options) on June 5, 2026. The grant is reported at $0.00 (no cash paid at grant) and therefore shows $0 in immediate value on the Form 4. This is an equity compensation award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-05; Form filed: 2026-06-16 (filed 11 days after the transaction, beyond the typical 2 business-day Form 4 deadline).
• Amount: 16,377 options; reported price: $0.00 (no cash exchanged in the filing).
• Shares/ownership after transaction: Not specified in the information provided in this summary.
• Footnote: 100% of the stock options granted on June 5, 2026 will vest on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholders.
• Filing timeliness: Late relative to the standard 2-business-day reporting requirement (the filing was submitted 11 days after the grant).

Context
This was a compensation grant of options to a company director, not an immediate exercise or sale. As a derivative award, these options must vest (per the footnote) before they can be exercised; there is no indication in this filing that any shares were sold or that a cashless exercise occurred. Director option grants are common as part of board compensation and do not by themselves indicate insider buying or selling sentiment.